Last news
BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701

BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701

...

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

...

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

...

NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE

NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE

...

VENUSTAS Launches the First Crowdfunding Campaign for Heated Camping Chair on Kickstarter

VENUSTAS Launches the First Crowdfunding Campaign for Heated Camping Chair on Kickstarter

...

China Cycle 2023: CST debuts CST COREX two-wheeled tire product, promotes sustainable development for ESG project globally

China Cycle 2023: CST debuts CST COREX two-wheeled tire product, promotes sustainable development for ESG project globally

...

Hisense Named to Fortune China's ESG Influential Listing 2023

Hisense Named to Fortune China's ESG Influential Listing 2023

...

China's self-developed AR glasses X-Craft won the gold medal at the Geneva International Invention Exhibition

China's self-developed AR glasses X-Craft won the gold medal at the Geneva International Invention Exhibition

...

menu
menu